We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals

4 hedge funds and large institutions have $28.1K invested in Biodexa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding

Funds holding: 1 → 4 (+3)

1.94% more ownership

Funds ownership: 1.25% → 3.19% (+1.9%)

Holders
4
Holders Change
+3
Holders Change %
+300%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

BDRX Hedge Fund Activity: Q1 2025 in Review

4 of the 7,492 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2025, worth a combined $28.1K — down 4.1% from $29.3K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BDRX positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $40.6K.

  • 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2025, up from 1 in Q4 2024.
  • Funds reported $28.1K of Biodexa Pharmaceuticals stock for Q1 2025, down 4.1% quarter-over-quarter.
  • 3 funds opened new Biodexa Pharmaceuticals positions in Q1 2025 and 0 closed out, a net change of +3 holders.
  • The largest Biodexa Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $40.6K added.

Based on aggregated 13F filings for Q1 2025.